1) I Wonder If You Can Help with Regards to a Freedom of Information Request I Have for Biologics and Biosimilar Prescribing. C

FREEDOM OF INFORMATION ACT 2000

THE ROYAL CORNWALL HOSPITALS NHS TRUST RESPONSE TO INFORMATION REQUEST

Date Request Received: 28th May 2019 FOI Ref: 6568

Requested Information

1) I wonder if you can help with regards to a Freedom of Information request I have for Biologics and Biosimilar prescribing. Could you please provide me with following numbers of patients treated in the last 12 months (latest) 12 months possible) with the following drugs for either Rheumatology, Dermatology and Gastroenterology departments: Treatment Total Rheumatology Dermatology Gastroenterology Abatacept (Orencia) Adalimumab biosimilar (Amgevita) Adalimumab biosimilar (Hulio) Adalimumab (Humira) Adalimumab biosimilar (Hyrimoz) Adalimumab bioisimilar (Imraldi) Apremilast (Otezla) Baricitinib (Olumiant) Brodalumab (Kyntheum) Certolizumab (Cimzia) Dimethyl Fumarate (Skilarence) Etanercept (Enbrel) Etanercept Biosimilar (Benepali) Etanercept Biosimilar (Erelzi) Golimuab (Simponi) Guselkumab (Tremfya) Jemma Dunstan, Information Governance Team V1 Review Date: 2022 Page 1 of 3

Infliximab (Flixabi) Infliximab (Inflectra) Infliximab (Remicade) Infliximab (Remsima) Ixekizumab (Taltz) Rituximab (Mabthera) Rituximab Biosimilar (Rixathon) Rituximab Biosimilar (Truxima) Sarilumab (Kevzara) Secukinumab (Cosentyx) Tildrakizumab (Ilumetri) Tocilizumab (Ro Actemra) Tofacitinib (Xeljanz) Ustekinumab (Stelara) Vedolizumab (Entyvio)

Response

1) Please be advised the Royal Cornwall Hospitals Trust is unable to provide a breakdown of drugs issued to areas such as Rheumatology, Dermatology and Gastroenterology as the information is not recorded in this way. Please see the table below for the total number of patients treated with the following Treatments

Treatment Total Abatacept (Orencia) 19 Adalimumab biosimilar 4 (Amgevita) Adalimumab biosimilar 2 (Hulio) Adalimumab (Humira) 428 Adalimumab biosimilar 0 (Hyrimoz) Adalimumab bioisimilar 393 (Imraldi) Apremilast 59 Baricitinib 65

Jemma Dunstan, Information Governance Team V1 Review Date: 2022 Page 2 of 3

Brodalumab 5 Certolizumab (Cimzia) 55 Dimethyl Fumarate 25 Dimethyl Fumarate 5 (Skilarence) Etanercept (Enbrel) 51 Etanercept Biosimilar 248 (Benepali) Etanercept Biosimilar 0 (Erelzi) Golimuab (Simponi) 38 Guselkumab (Tremfya) 0 Infliximab (Flixabi) 84 Infliximab (Inflectra) 93 Infliximab (Remicade) 6 Infliximab (Remsima) 2 Ixekizumab (Taltz) 0 Rituximab (Mabthera) 4 Rituximab 26 Rituximab Biosimilar 268 (Truxima) Sarilumab (Kevzara) 2 Secukinumab (Cosentyx) 77 Tildrakizumab (Ilumetri) Tocilizumab (Ro Actemra) 84 Tofacitinib (Xeljanz) 83 Ustekinumab (Stelara) 37 Vedolizumab (Entyvio) 45

Attachment(s) None

Date Response Sent: June 2019

Jemma Dunstan, Information Governance Team V1 Review Date: 2022 Page 3 of 3